EQT Enters Advanced Talks to Acquire Qiagen
The investment firm has submitted a bid exceeding $50 per share as Qiagen evaluates multiple buyout offers.
Updated on Oct. 20, 2026 in Corporate Finance
Live Poll
Do you support the consolidation of major diagnostic testing companies through private equity acquisitions?
Private equity firm EQT has entered advanced negotiations to acquire Qiagen, according to reports. Competitor KKR has also submitted a bid for the company, which holds a market capitalization of 8.57 billion euros.
Why it matters
The board of directors is currently meeting to evaluate strategic options after signaling interest in a potential sale earlier this year. However, there is no guarantee that these discussions will ultimately result in a transaction.
Qiagen currently maintains a market capitalization of 8.57 billion euros. Shares surged more than 6% in afternoon trading following reports of the competitive bidding environment.
The players
EQT
This global investment organization is based in Sweden and manages a wide portfolio of companies across various sectors.
Qiagen
This company is a provider of sample and assay technologies for molecular diagnostics and testing.
KKR
This United States-based global investment firm specializes in private equity, energy, and infrastructure assets.
The details
The board is meeting this week to deliberate on offers from EQT and KKR after publicly stating in January that it was exploring strategic alternatives. Potential acquisition interest in the firm was first reported in July.
Timeline
January 2026: Qiagen announced it was evaluating strategic options.
July 2026: Buyout firms were linked to a potential Qiagen acquisition.
October 20, 2026: Reports emerged of advanced talks between EQT and Qiagen.
Week of October 19, 2026: The Qiagen board meets to decide on the potential deal.
Market Dynamics
The bidding war for Qiagen reflects the broader trend of 2026 private equity consolidation within the healthcare diagnostics sector. This competitive environment indicates how investment firms are vying to capture major market share in specialized testing and technology.
Shareholders may see significant volatility in stock value as the board evaluates the competing acquisition bids. Institutional and retail investors should monitor future board announcements to determine if a takeover offer is officially accepted.
The takeaway
The move by EQT and KKR highlights the significant premium placed on established players in the diagnostics technology space. Investors and stakeholders should anticipate further news once the board concludes its deliberation on the proposed buyout offers.
Further reading
Learn more about the latest industry shifts at Corporate Finance.
Live Poll
Do you support the consolidation of major diagnostic testing companies through private equity acquisitions?
